Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1986 1
1987 1
1988 2
1990 1
1991 2
1992 1
1993 1
1998 2
2006 1
2010 1
2012 1
2014 4
2015 7
2016 18
2017 14
2018 8
2019 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31004554

61 results

Results by year

Filters applied: . Clear all
Page 1
Photosafety of the antidiabetic drug sitagliptin.
Dubón A, Morera I, García-Lainez G, Sahuquillo A, Rodríguez M, Miranda MA, Andreu I. Dubón A, et al. Photodermatol Photoimmunol Photomed. 2019 Sep;35(5):375-377. doi: 10.1111/phpp.12475. Epub 2019 May 24. Photodermatol Photoimmunol Photomed. 2019. PMID: 31004554 No abstract available.
Griseofulvin-induced photodermatitis--report of six cases.
Kojima T, Hasegawa T, Ishida H, Fujita M, Okamoto S. Kojima T, et al. J Dermatol. 1988 Feb;15(1):76-82. doi: 10.1111/j.1346-8138.1988.tb03654.x. J Dermatol. 1988. PMID: 2969014 No abstract available.
Rilmenidine-induced photosensitivity reaction.
Mota AV, Vasconcelos C, Correia TM, Barros MA, Mesquita-Guimarães J. Mota AV, et al. Photodermatol Photoimmunol Photomed. 1998 Jun-Aug;14(3-4):132-3. doi: 10.1111/j.1600-0781.1998.tb00027.x. Photodermatol Photoimmunol Photomed. 1998. PMID: 9779502 No abstract available.
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O, Kahle M, Deacon CF, Holst JJ, Nauck MA. Baranov O, et al. Diabetes Obes Metab. 2016 Nov;18(11):1100-1109. doi: 10.1111/dom.12706. Epub 2016 Aug 17. Diabetes Obes Metab. 2016. PMID: 27300579 Clinical Trial.
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Ahrén B, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):341-354. doi: 10.1016/S2213-8587(17)30092-X. Epub 2017 Apr 3. Lancet Diabetes Endocrinol. 2017. PMID: 28385659 Clinical Trial.
61 results